Awaiting development: Guidance and quality standards
Showing 361 to 364 of 364
| Title | Type |
|---|---|
| Zilovertamab vedotin in combination for treating relapsed or refractory diffuse large B-cell lymphoma | Technology appraisal guidance |
| Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637] | Technology appraisal guidance |
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |